Unique ID issued by UMIN | UMIN000007057 |
---|---|
Receipt number | R000008201 |
Scientific Title | The effect of chronotherapy with the angiotensin-antagonist in hypertension with sleep apnea syndrome. |
Date of disclosure of the study information | 2012/01/12 |
Last modified on | 2018/10/10 22:11:15 |
The effect of chronotherapy with the angiotensin-antagonist in hypertension with sleep apnea syndrome.
The effect of chronotherapy with the angiotensin-antagonist in hypertension with sleep apnea syndrome.
The effect of chronotherapy with the angiotensin-antagonist in hypertension with sleep apnea syndrome.
The effect of chronotherapy with the angiotensin-antagonist in hypertension with sleep apnea syndrome.
Japan |
Sleep Apnea Syndrome
Medicine in general | Cardiology | Pneumology |
Others
NO
To evaluate the impact on the circadian pattern of blood pressure on modifying the time of ARB treatment, body weight, insulin resistance and metabolic markers.
Efficacy
Confirmatory
Explanatory
Phase IV
Blood pressure
Heart rate, Urine albumin, CRP, Body weight/Waist circumference, Adiponectin
Interventional
Cross-over
Randomized
Individual
Open -no one is blinded
Active
NO
NO
Institution is not considered as adjustment factor.
NO
Central registration
2
Treatment
Medicine |
We randomly assign hypertensive patients with sleep apnea to treatment with irbesartan, 100mg daily, with morning administration or with evening administration for 24 weeks. After 12 weeks, each administration protocol is switched according to a crossover design.
We randomly assign hypertensive patients with sleep apnea to treatment with irbesartan, 100mg daily, with morning administration or with evening administration for 24 weeks. After 12 weeks, each administration protocol is switched according to a crossover design.
20 | years-old | <= |
80 | years-old | >= |
Male and Female
1. Patient with sleep apnea syndrome treated with oral appliance or nasal CPAP.
2. Hypertensive patient diagnosed by JSH 2009.
3. Patient should be treated with good compliance by oral appliance or nasal CPAP (usage: >=4 hours daily and >=5 days)
1. Patient from whom written informed consent is not obtained.
2. Not hypertensive patient.
3. Patient who has the hypersensitivity to irbesartan.
4. Pregnant woman and possible possible pregnant woman.
30
1st name | |
Middle name | |
Last name | Meiyo Tamaoka |
Tokyo medical and dental university
Graduate School of Medical and Dental Sciences
1-5-45, Yushima, Bunkyo-ku, Tokyo, 113-8519, JAPAN
81-3-5803-4967
meiyou2.pulm@tmd.ac.jp
1st name | |
Middle name | |
Last name | Meiyo Tamaoka |
Tokyo Medical & Dental University
University Hospital of Medicine
1-5-45, Yushima, Bunkyo-ku, Tokyo
81-3-5803-4967
http://www.tmd.ac.jp/med/pulm/sleep/index.html
meiyou2.pulm@tmd.ac.jp
Tokyo Medical & Dental University, Graduate School of Medical and Dental Sciences, Department of Sleep Modulatory Medicine
Tokyo Medical & Dental University, Graduate School of Medical and Dental Sciences, Department of Sleep Modulatory Medicine
Self funding
Japan
NO
2012 | Year | 01 | Month | 12 | Day |
Unpublished
Completed
2011 | Year | 08 | Month | 25 | Day |
2011 | Year | 12 | Month | 01 | Day |
2013 | Year | 12 | Month | 01 | Day |
2014 | Year | 12 | Month | 01 | Day |
2015 | Year | 04 | Month | 01 | Day |
2015 | Year | 08 | Month | 01 | Day |
2012 | Year | 01 | Month | 12 | Day |
2018 | Year | 10 | Month | 10 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000008201